Table 2 Clinicopathological findings in patients on sirolimus versus other immunosuppressive therapy

Age, mean, years

51.1 ± 13.25

54.3 ± 15.39

ns

Gender, M*

10 (62.5)

8 (66.7)

ns

   F

6 (37.5)

4 (33.3)

ns

Time to lung biopsy, mean, months

44.7 ± 52.04

128.3 ± 89.32

0.01

Neoplasia, total, n (%)

2 (12.5)

7 (58.3)

0.03

   Carcinoma, n (%)

1 (6.25)

4 (33.3)

ns

   Lymphoproliferative disorders, n (%)

1 (6.25)

3 (25.0)

ns

Diffuse parenchymal lung disease, n (%)

6 (37.5)

3 (25.0)

ns

   PH, n (%)

2 (12.5)

1 (8.3)

ns

   PH and DAD, n (%)

1 (6.25)

0

-

   PH and PAP, OP, n (%)

1 (6.25)

0

-

   OP, n (%)

2 (12.5)

1 (8.3)

ns

   PAP, n (%)

0

1 (8.3)

-

Necrosis/infectious granulomas, n (%)

4 (25.0)

1 (8.3)

ns

Minimal histological findings, n (%)

4 (25.0)

1 (8.3)

ns